Arcutis Biotherapeutics (ARQT) Retained Earnings (2019 - 2026)

Arcutis Biotherapeutics' Retained Earnings history runs 8 years deep, the most recent figure standing at -$1.1 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 820900.0% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 820900.0% YoY), while the FY2025 annual figure was -$1.1 billion, down 1.44% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.1 billion, down from -$1.1 billion in the prior quarter.
• The five-year high for Retained Earnings was $1.3 billion in Q3 2025, with the low at -$1.2 billion in Q2 2025.
• The 5-year median for Retained Earnings is -$1.1 million (2022), against an average of -$151.7 million.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings surged 246354.41% in 2025, then tumbled 820900.0% in 2026.
• Arcutis Biotherapeutics' Retained Earnings stood at -$1.1 million in 2022, then sank by 90314.73% to -$981.9 million in 2023, then retreated by 14.26% to -$1.1 billion in 2024, then dropped by 1.44% to -$1.1 billion in 2025, then retreated by 0.99% to -$1.1 billion in 2026.
• Business Quant data shows ARQT's Retained Earnings at -$1.1 billion in Q1 2026, -$1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.